The DOI matches its Crossref record; 263 of the 263 references it cites were found in a registry or an index.
Vulnerability of mesostriatal dopaminergic neurons in Parkinson’s disease
Open accessAbstract
The term vulnerability was first associated with the midbrain dopaminergic neurons 85 years ago, before they were identified as monoaminergic neurons, when Foix and Nicolesco (1925) reported the loss of neuromelanin containing neurons in the midbrain of patients with post-encephalitic Parkinson's disease (PD). A few years later, Hassler (1938) showed that degeneration is more intense in the ventral tier of the substantia nigra compacta than in its dorsal tier and the ventral tegmental area (VTA), outlining the concept of differential vulnerability of midbrain dopaminergic (DA-) neurons. Nowadays, we know that other neuronal groups degenerate in PD, but the massive loss of nigral DA-cells is its pathological hallmark, having a pivotal position in the pathophysiology of the disease as it is responsible for the motor symptoms. Data from humans as well as cellular and animal models indicate that DA-cell degeneration is a complex process, probably precipitated by the convergence of different risk factors, mediated by oxidative stress, and involving pathogenic factors arising within the DA-neuron (intrinsic factors), and from its environment and distant interconnected brain regions (extrinsic factors). In light of current data, intrinsic factors seem to be preferentially involved in the first steps of the degenerative process, and extrinsic factors in its progression. A controversial issue is the relative weight of the impairment of common cell functions, such as energy metabolism and proteostasis, and specific dopaminergic functions, such as pacemaking activity and DA handling, in the pathogenesis of DA-cell degeneration. Here we will review the current knowledge about the relevance of these factors at the beginning and during the progression of PD, and in the differential vulnerability of midbrain DA-cells.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Although dopaminergic neurons throughout the midbrain degenerate during Parkinson’s disease, death of SNc dopamine neurons is more pronounced (Gonzalez-Hernandez et al., 2010).”
From Local cues establish and maintain region-specific phenotypes of basal ganglia microglia (2017) · cites this paper as Gonzalez-Hernandez et al., 2010
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
1 retracted
Items 201–263 of 263
Plaitakis, A., & Shashidharan, P. (2000) · Journal of Neurology · doi:10.1007/pl00007757 · Cited by 142
Dopamine transporter mRNA: dense expression in ventral midbrain neurons
Shimada, S., Kitayama, S., Walther, D. M., & Uhl, G. R. (1992) · Molecular Brain Research · doi:10.1016/0169-328x(92)90220-6 · Cited by 140
Shima, T., Sarna, T., Swartz, H. M., Stroppolo, A., Gerbasi, R., & Zecca, L. (1997) · Free Radical Biology and Medicine · doi:10.1016/s0891-5849(96)00623-5 · Cited by 135
Increase in Peripheral CD4 Bright+ CD8 Dull+ T Cells in Parkinson Disease
Hisanaga, K., 浅黄美沙, Itoyama, Y., & Iwasaki, Y. (2001) · Archives of Neurology · doi:10.1001/archneur.58.10.1580 · Cited by 131
Marshall, J. F., O’Dell, S. J., Navarrete, R. J., & Rosenstein, A. J. (1990) · Neuroscience · doi:10.1016/0306-4522(90)90187-9 · Cited by 130
Dopamine Uptake is Differentially Regulated in Rat Striatum and Nucleus Accumbens
Missale, C., Castelletti, L., Govoni, S. M., Spano, P., Trabucchi, M., & Hanbauer, I. (1985) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.1985.tb05473.x · Cited by 125
Aging and the nigrostriatal dopamine system: a non-human primate study.
Irwin, I., DeLanney, L. E., McNeill, T. H., Chan, P., Forno, L. S., Murphy, G. M., Monte, D. A. D., Sandy, M. S., & Jw, L. (1994) · PubMed · Cited by 125
Aging of the nigrostriatal system in the squirrel monkey
McCormack, A. L., Monte, D. A. D., Delfani, K., Irwin, I., DeLanney, L. E., Langston, J. W., & Janson, A. M. (2004) · The Journal of Comparative Neurology · doi:10.1002/cne.20036 · Cited by 120
Zafar, K. S., Siegel, D. M., & Ross, D. (2006) · Molecular Pharmacology · doi:10.1124/mol.106.024703 · Cited by 120
Dopamine transporter mRNA expression is intense in rat midbrain neurons and modest outside midbrain
Cerruti, C., Walther, D. M., Kuhar, M. J., & Uhl, G. R. (1993) · Molecular Brain Research · doi:10.1016/0169-328x(93)90187-t · Cited by 119
Varastet, M., RICHE, D., Mazière, M., & Hantraye, P. (1994) · Neuroscience · doi:10.1016/0306-4522(94)90006-x · Cited by 118
Iribe, Y., Moore, K., Pang, K. C. H., & Tepper, J. M. (1999) · Journal of Neurophysiology · doi:10.1152/jn.1999.82.2.925 · Cited by 117
Modifications of the iron–neuromelanin system in Parkinson's disease
Fasano, M., Bergamasco, B., & Lopiano, L. (2006) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.2005.03638.x · Cited by 117
Enochs, W. S., Sarna, T., Zecca, L., Riley, P. A., & Swartz, H. M. (1994) · Journal of Neural Transmission - Parkinsons Disease and Dementia Section · doi:10.1007/bf02260963 · Cited by 116
Autoradiography of [14C]paraquat or [14C]diquat in frogs and mice: Accumulation in neuromelanin
Lindquist, N. G., Larsson, B. S., & Lydén‐Sokolowski, A. (1988) · Neuroscience Letters · doi:10.1016/0304-3940(88)90002-x · Cited by 114
Rodrı́guez, M., Barroso‐Chinea, P., Abdala, P., Obeso, J. A., & González‐Hernández, T. (2001) · Experimental Neurology · doi:10.1006/exnr.2000.7624 · Cited by 113
Dopamine Quinones Activate Microglia and Induce a Neurotoxic Gene Expression Profile
Kuhn, D. M., Francescutti‐Verbeem, D. M., & Thomas, D. M. (2006) · Annals of the New York Academy of Sciences · doi:10.1196/annals.1369.003 · Cited by 111
Midbrain dopaminergic neurons in the mouse: co-localization with Calbindin-D28k and calretinin
Liang, C., Sinton, C. M., & German, D. C. (1996) · Neuroscience · doi:10.1016/0306-4522(96)00228-x · Cited by 104
Changes in somatodendritic but not terminal dopamine regulation in aged rhesus monkeys
Gerhardt, G. A., Cass, W. A., Ai, Y., Zhang, Z., & Gash, D. M. (2001) · Journal of Neurochemistry · doi:10.1046/j.0022-3042.2001.00684.x · Cited by 102
González‐Hernández, T., Barroso‐Chinea, P., Cruz‐Muros, I., Pérez-Delgado, M. D. M., & Rodrı́guez, M. (2004) · The Journal of Comparative Neurology · doi:10.1002/cne.20323 · Cited by 96
Muñoz, A., Rey, P., Guerra, M. J., Méndez‐Álvarez, E., Soto‐Otero, R., & Labandeira-García, J. L. (2006) · Neuropharmacology · doi:10.1016/j.neuropharm.2006.03.004 · Cited by 88
Airaksinen, M. S., Thoenen, H., & Meyer, M. (1997) · European Journal of Neuroscience · doi:10.1111/j.1460-9568.1997.tb01360.x · Cited by 88
Paraquat: The Red Herring of Parkinson's Disease Research
Miller, G. W. (2007) · Toxicological Sciences · doi:10.1093/toxsci/kfm223 · Cited by 87
Wilms, H., Rosenstiel, P. C., Romero‐Ramos, M., Arlt, A., Schäfer, H., Seegert, D., Kahle, P. J., Odoy, S., Claasen, J.-H., Holzknecht, C., et al. (2009) · International Journal of Immunopathology and Pharmacology · doi:10.1177/039463200902200405 · Cited by 84
Hurd, Y. L., Pristupa, Z. B., Herman, M. M., Niznik, H. B., & Kleinman, J. E. (1994) · Neuroscience · doi:10.1016/0306-4522(94)90535-5 · Cited by 81
Zeevalk, G. D., Bernard, L. P., & Nicklas, W. J. (1998) · Journal of Neurochemistry · doi:10.1046/j.1471-4159.1998.70041421.x · Cited by 81
Indomethacin protects against neurodegeneration caused by MPTP intoxication in mice.
Kurkowska-Jastrzębska, I., Babiuch, M., Joniec, I., Przybyłkowski, A., Członkowski, A., & Członkowska, A. (2002) · International Immunopharmacology · doi:10.1016/s1567-5769(02)00078-4 · Cited by 80
Basal Ganglia Control of Substantia Nigra Dopaminergic Neurons
Lee, C. R., & Tepper, J. M. (2009) · Springer eBooks · doi:10.1007/978-3-211-92660-4_6 · Cited by 76
Impact of High-Frequency Stimulation Parameters on the Pattern of Discharge of Subthalamic Neurons
García, L., D’Alessandro, G., Fernagut, P., Bioulac, B. H., & Hammond, C. (2005) · Journal of Neurophysiology · doi:10.1152/jn.00496.2005 · Cited by 76
Choi, Y. M., Kim, S. H., Chung, S., Uhm, D. Y., & Park, M. K. (2006) · Journal of Neuroscience · doi:10.1523/jneurosci.3158-06.2006 · Cited by 73
Modulation by neuromelanin of the availability and reactivity of metal ions
Swartz, H. M., Sarna, T., & Zecca, L. (1992) · Annals of Neurology · doi:10.1002/ana.410320712 · Cited by 73
The insecticide target in the PSST subunit of complex I
Schuler, F., & Casida, J. E. (2001) · Pest Management Science · doi:10.1002/ps.364 · Cited by 72
Approaches to Prevent Dopamine Quinone-Induced Neurotoxicity
Miyazaki, I., & Asanuma, M. (2008) · Neurochemical Research · doi:10.1007/s11064-008-9843-1 · Cited by 71
Is There a Rationale for Neuroprotection Against Dopamine Toxicity in Parkinson's Disease?
Barzilai, A., Melamed, E., & Shirvan, A. (2001) · Cellular and Molecular Neurobiology · doi:10.1023/a:1010991020245 · Cited by 70
Afonso‐Oramas, D., Cruz‐Muros, I., de la Rosa, D. Á., Abreu, P. M., Giráldez, T., Castro‐Hernández, J., Salas-Hernández, J., Lanciego, J. L., Rodrı́guez, M., & González‐Hernández, T. (2009) · Neurobiology of Disease · doi:10.1016/j.nbd.2009.09.002 · Cited by 70
Hurley, S. D., O'Banion, M., Song, D. D., Arana, F. S., Olschowka, J., & Haber, S. (2003) · Experimental Neurology · doi:10.1016/s0014-4886(03)00273-5 · Cited by 69
Astroglial plasticity and glutamate function in a chronic mouse model of Parkinson's disease
Dervan, A. G., Meshul, C. K., Beales, M., McBean, G. J., Moore, C., Totterdell, S., Snyder, A. K., & Meredith, G. E. (2004) · Experimental Neurology · doi:10.1016/j.expneurol.2004.07.004 · Cited by 69
Mizuno, Y., Sone, N., Suzuki, K., & Saitoh, T. (1988) · Journal of the Neurological Sciences · doi:10.1016/0022-510x(88)90010-x · Cited by 66
Fogel, R., Zhang, X., & Renehan, W. E. (1996) · The Journal of Comparative Neurology · doi:10.1002/(sici)1096-9861(19960101)364:1 · Cited by 65
Calbindin D28k-containing neurons are restricted to the medial substantia nigra in humans
McRitchie, D. A., & Halliday, G. M. (1995) · Neuroscience · doi:10.1016/0306-4522(94)00483-l · Cited by 54
Features of the Dopaminergic Neurotoxin MPTP
Kopin, I. J. (1992) · Annals of the New York Academy of Sciences · doi:10.1111/j.1749-6632.1992.tb24527.x · Cited by 53
Matteo, V. D., Pierucci, M., Giovanni, G. D., Santo, A. D., Poggi, A., Benigno, A., & Esposito, E. (2006) · Brain Research · doi:10.1016/j.brainres.2006.04.013 · Cited by 53
Cruz‐Muros, I., Afonso‐Oramas, D., Abreu, P. M., Barroso‐Chinea, P., Rodrı́guez, M., González, M. C., & González‐Hernández, T. (2006) · Experimental Neurology · doi:10.1016/j.expneurol.2006.10.004 · Cited by 52
Victoroff, J., Zarow, C., Mack, W. J., Hsu, E., & Chui, H. C. (1996) · Archives of Neurology · doi:10.1001/archneur.1996.00550050058024 · Cited by 50
Borland, M., Mohanakumar, K. P., Rubinstein, J. D., Keeney, P. M., Xie, J., Capaldi, R., Dunham, L. D., Trimmer, P. A., & Bennett, J. P. (2008) · Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease · doi:10.1016/j.bbadis.2008.09.014 · Cited by 46
A stereological study of substantia nigra in young and old rhesus monkeys
Pakkenberg, H., Andersen, B. B., Burns, R. S., & Pakkenberg, B. (1995) · Brain Research · doi:10.1016/0006-8993(95)00678-j · Cited by 44
Parkin affects mitochondrial function and apoptosis in neuronal and myogenic cells
Kuroda, Y., Mitsui, T., Kunishige, M., & Matsumoto, T. (2006) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2006.06.201 · Cited by 41
Mitochondria in the aetiology and pathogenesis of Parkinson's disease
Schapira, A. H. V. (1999) · Parkinsonism & Related Disorders · doi:10.1016/s1353-8020(99)00029-2 · Cited by 41
McNaught, K. S. P., JnoBaptiste, R., Jackson, T., & Jengelley, T. (2009) · Synapse · doi:10.1002/syn.20719 · Cited by 37
Critical evaluation of the Braak staging scheme for Parkinson's disease
Jellinger, K. A. (2009) · Annals of Neurology · doi:10.1002/ana.21638 · Cited by 36
Salazar, M. M., Td, S., & Pn, P. (1978) · PubMed · Cited by 35
Cruz‐Muros, I., Afonso‐Oramas, D., Abreu, P. M., Rodrı́guez, M., González, M. C., & González‐Hernández, T. (2007) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2007.04.003 · Cited by 33
Lewy bodies in Parkinson's disease: Protectors or perpetrators?
Harrower, T., Michell, A. W., & Barker, R. A. (2005) · Experimental Neurology · doi:10.1016/j.expneurol.2005.06.002 · Cited by 31
Mitochondrial Cell Death Control in Familial Parkinson Disease
Kroemer, G., & Blomgren, K. (2007) · PLoS Biology · doi:10.1371/journal.pbio.0050206 · Cited by 29
HtrA2 and Parkinson's disease: think PINK?
Alnemri, E. S. (2007) · Nature Cell Biology · doi:10.1038/ncb1107-1227 · Cited by 28
Parkinson's Disease: Return of an Old Prime Suspect
Sulzer, D. L., & Schmitz, Y. (2007) · Neuron · doi:10.1016/j.neuron.2007.06.023 · Cited by 28
Analysis of targeted mutation in DJ-1 on cellular function in primary astrocytes
Ashley, A. K., Hanneman, W. H., Katoh, T., Moreno, J. A., Pollack, A., Tjalkens, R. B., & Legare, M. E. (2008) · Toxicology Letters · doi:10.1016/j.toxlet.2008.11.008 · Cited by 26
The Ubiquitin-Proteasome System and Proteasome Inhibitors in Central Nervous System Diseases
Shah, I. M., & Napoli, M. D. (2007) · Cardiovascular & Haematological Disorders - Drug Targets · doi:10.2174/187152907782793572 · Cited by 24
Foix, C., & Nicolesco, J. (1925) · Masson eBooks · Cited by 15
Turski, W. A., & Lachowicz, L. (1991) · International Journal of Biochemistry · doi:10.1016/0020-711x(91)90113-2 · Cited by 14
Phenotype, Compartmental Organization and Differential Vulnerability of Nigral Dopaminergic Neurons
González‐Hernández, T., Afonso‐Oramas, D., & Cruz‐Muros, I. (2009) · Springer eBooks · doi:10.1007/978-3-211-92660-4_2 · Cited by 13
PLATELET MITOCHONDRIAL-FUNCTION IN PARKINSONS-DISEASE
Krige, D., CARROLL, M., Cooper, J. A. D., MARSDEN, C., & Schapira, A. H. V. (1992) · UCL Discovery (University College London) · Cited by 12
Zahm (1996) · doi:10.1002/(sici)1096-9861(19960108)364:2
Research works printed but not linked: 1
- Przedborski S. Jackson-Lewis V. (1998). Mechanisms of MPTP toxicity. Mov. Disord. 13 (Suppl. 1), 35– 38 9613716
Cited by
Sorted by citations
Mhyre, T. R., Boyd, J. T., Hamill, R. W., & Maguire‐Zeiss, K. A. (2012) · Sub-cellular biochemistry/Subcellular biochemistry · doi:10.1007/978-94-007-5416-4_16 · Cited by 463
“Tretiakoff named the eponymous Lewy body inclusions in honor of Lewy’s work and a more detailed description of PD pathology by Foix & Nicolesco subsequently identified the specific loss of pigmented, neuromelanin containing neurons in the SN (Gonzalez-Hernandez et al. 2010).”
BackgroundLocal cues establish and maintain region-specific phenotypes of basal ganglia microglia
De Biase, L. M., Schuebel, K. E., Fusfeld, Z. H., Jair, K., Hawes, I. A., Cimbro, R., Zhang, H.-Y., Liu, Q.-R., Shen, H., Xi, Z.-X., et al. (2017) · Neuron · doi:10.1016/j.neuron.2017.06.020 · Cited by 432
“Although dopaminergic neurons throughout the midbrain degenerate during Parkinson’s disease, death of SNc dopamine neurons is more pronounced (González-Hernández et al., 2010).”
M1 and M2 immune activation in Parkinson’s Disease: Foe and ally?
Moehle, M. S., & West, A. B. (2014) · Neuroscience · doi:10.1016/j.neuroscience.2014.11.018 · Cited by 209
“Through decades of work, it is thought that cells vulnerable to neurodegeneration in PD are particularly sensitive to secreted factors associated with M1 activation (Gonzalez-Hernandez et al., 2010).”
BackgroundDuda, J., Pötschke, C., & Liss, B. (2016) · Journal of Neurochemistry · doi:10.1111/jnc.13572 · Cited by 153
“…mishandling, impairment of the ubiquitin–proteasome pathway and inflammation contribute to SN DA degeneration and sporadic as well as familial PD (Gonzalez-Hernandez et al. 2010; Guzman et al. 2010; Obeso and Lanciego 2011; Coskun et al. 2012; Sulzer and Surmeier 2013; Beilina and Cookson 2015;…”
BackgroundPatricio, F., Morales-Andrade, A. A., Patricio-Martínez, A., & Limón, I. D. (2020) · Frontiers in Pharmacology · doi:10.3389/fphar.2020.595635 · Cited by 129
“There is evidence that the dopaminergic neurons of the SNpc are vulnerable to oxidative damage, as they present low levels of antioxidant enzymes, such as glutathione peroxidase, and high levels of pro-oxidants, such as free iron and neuromelanin (González-Hernández et al., 2010).”
Background
Metadata
- Authors
- González-Hernández, T.
- Venue
- Frontiers in Neuroanatomy
- Publisher
- Frontiers Media SA
- Published
- 2010
- Volume
- 4
- Pages
- 140-140
- ISSN
- 1662-5129 (ISSN-L)
- PMC
- PMC2978035
- OpenAlex
- W2123571361
- Cited by
- 65
- References
- 263
- Citations by year
- 2026: 2 · 2025: 1 · 2024: 1 · 2023: 3 · 2022: 1 · 2021: 2 · 2020: 4 · 2019: 5 · 2018: 2 · 2017: 10 · 2016: 6 · 2015: 3 · 2014: 7 · 2013: 2 · 2012: 11
- FWCI
- 3.44
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- cc-by
- Locations
- Frontiers in Neuroanatomy (publishedVersion, cc-by)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- Funders
- Fundación Canaria de Investigación y Salud
- Department of Science and Technology, Ministry of Science and Technology, India
- Ministerio de Ciencia e Innovación
- Centro de Investigación Biomédica en Red sobre Enfermedades Neurodegenerativas
- Instituto de Salud Carlos III
- Topics
- Health Sciences › Medicine › Clinical Neurology › Parkinson's Disease Mechanisms and Treatments
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Nuclear Receptors and Signaling
- Health Sciences › Medicine › Clinical Neurology › Deep Brain Stimulation and Movement Disorders
- Keywords
- Parkinson's disease, substantia nigra pars compacta, ventral tegmental area, oxidative stress, intrinsic and extrinsic risk factors, energy metabolism, proteostasis
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
